Screener
Jade Biosciences JBIO EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Jade Biosciences’s reported figures.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
FAQ
- What is Jade Biosciences's EBITDA?
- Jade Biosciences (JBIO) reported EBITDA of -$43.44M in Q1 2026.
- How has Jade Biosciences's EBITDA changed year-over-year?
- Jade Biosciences's EBITDA decreased by 85.8% year-over-year, from -$23.38M to -$43.44M.
- What is the long-term trend for Jade Biosciences's EBITDA?
- Over 4 years (2021 to 2025), Jade Biosciences's EBITDA has grown at a 49.0% compound annual growth rate (CAGR), from -$23.01M to -$113.52M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Jade Biosciences's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude